Korea Research Institute of Bioscience and Biotechnology

Dongguk University Industry-Academic Cooperation Foundation

Yonsei University

Mi Sun Won

Bo Kyung Kim

Kyeong Seok Lee

Young Il Yeom

Kyung Sook Chung

Hyun Seung Ban

Dong Uk Kim

Hee Gu Lee

Kyung-Sook Chung

Eun Young Song

Hyang Sook Yoo

Young Ho Kim

Hwan Mook Kim

Han Oh Park

Seung-Hee Lee

Jae Wha Kim

Jung Joon Lee

Jae Ho Cheong

Hong-Sub Lee

Young-Ju Lee

Dong Sup Kim

Shin Jung Choi

Chang Woo Lee

Kyung Chan Park

Song Kyu Park

Kiho Lee

Ki Hoon Lee

Seon-Young Kim

Ho Kyung Chun

Min Ah Kang

Hye Mi Lee

Jae Hun Cheong

Min Ho Lee

Young Joo Jang

Hyong Bai Kim

Yinglan Jin

Hyang Sin Lee

Chang Mo Kang

Jeong Hae Choi

Seung Tae Baek

Ki Cheol Park

Soon Woo Nam

Joo-Young Im

Sang Jo Han

Kyoung-Jin Oh

Kwang Lae Hoe

Mi Young Nam

Kyung Sun Heo

Jo Young Park

Seohyun Son

In Seong Choe

Mi Young Park

Ji Won Ahn

The present invention relates to a method for preventing or treating cancer comprising administering a Synaptotagmin 11 (SYT11) inhibitor to a subject, a method for diagnosing cancer comprising measuring an expression level of SYT11, and a method for screening a preparation for treating cancer.

Method for preventing or treating cancer using SYT11 inhibitor

The present invention relates to a pharmaceutical composition for treating cancer, containing cytochrome b5 reductase 3 (CYB5R3) protein as an active ingredient. Over-expression of CYB5R3 in cancer cells results in significant reduction of hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;) expression, which leads inhibition of cancer cells growth in vitro and in vivo. Thus, the CYB5R3 gene or protein of the present invention can be useful as an active ingredient of a pharmaceutical composition for treating cancer.

Pharmaceutical composition for preventing and treating cancer, containing CYB5R3 gene or protein as active ingredient

A method comprising transformingwith a deletion cassette, constructed by four-round serial PCR, block PCR or total gene synthesis, containing a homologous recombination site is provided for preparing gene-targeted heterozygous deletion. Also provided are gene-targeted hetero2ygous deletionmutants prepared by the method, and a library of gene-targeted heterozygous deletionmutants. Further, the library is useful in constructing a method and a kit for screening a drug's modes of action.

[object Object]

The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1&#x3b1;, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, &#x3b2;-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.

Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient

Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided. Further, a composition for the treatment and prevention of cancer, comprising an oligonucleotide inhibiting the expression of a gene encoding the GPCR polypeptide or an antibody against the GPCR protein, and a method for screening a modulator of the GPCR protein or a cancer therapeutic agent are provided.

G protein coupled receptor protein and use thereof

The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Aryloxy phenoxy acrylic compound having HIF-1 inhibition activity, method for preparing same, and pharmaceutical composition containing same as an active ingredient

Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.

Characterization of ESM-1 as a tumor associated marker of colorectal cancer

Growing community of inventors

Daejeon, South Korea

Mi Sun Won